Catalysts
ARQT Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
ARQTArcutis Biotherapeutics, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum76
- Value65
- Quality76
- Risk resilience46
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 76/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 16.31%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | — | $0.18 | $0.06 | -66.7% | $142.59M | $143.92M |
| Aug 5, 2026 | — | $0.06 | $0.11 | +99.7% | $118.85M | $129.86M |
| May 6, 2026 | — | -$0.02 | -$0.09 | -350.0% | $103.68M | $105.4M |
| Feb 25, 2026 | — | $0.03 | $0.13 | +333.3% | $113.06M | $129.5M |
| Oct 28, 2025 | — | -$0.10 | $0.06 | +160.0% | $110.79M | $99.22M |
| Aug 6, 2025 | — | -$0.18 | -$0.13 | +27.8% | $80.63M | $81.5M |
| May 6, 2025 | — | -$0.21 | -$0.20 | +4.8% | $72.7M | $65.85M |
| Feb 25, 2025 | — | -$0.28 | -$0.09 | +67.9% | $60.52M | $71.36M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to $143.9 Million as Guidance Raised and Pipeline Expands
Release Date: November 04, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Net product
Related Links
ARQT Catalysts FAQ
What are the next catalysts for ARQT stock?
ARQT's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move ARQT stock?
Upcoming events that could move ARQT include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could ARQT's next earnings report affect the stock?
ARQT's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive ARQT stock higher?
ARQT could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt ARQT stock?
ARQT could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.